MedTrace Logo

Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide

NCT00899080 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood samples from patients with multiple myeloma who were treated with thalidomide or lenalidomide.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

GENETIC

gene expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

immunoenzyme technique

OTHER

laboratory biomarker analysis

OTHER

platelet aggregation test

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Suzanne Lentzsch, MD, PhD · University of Pittsburgh

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-04
Primary Completion
2008-08-04
Completion
2008-08-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00899080 on ClinicalTrials.gov